Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Stake Lessened by Motley Fool Asset Management LLC

Motley Fool Asset Management LLC lowered its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 4.3% in the fourth quarter, Holdings Channel.com reports. The firm owned 149,443 shares of the biopharmaceutical company’s stock after selling 6,661 shares during the period. Motley Fool Asset Management LLC’s holdings in Ultragenyx Pharmaceutical were worth $7,146,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Covestor Ltd raised its holdings in shares of Ultragenyx Pharmaceutical by 392.1% during the third quarter. Covestor Ltd now owns 748 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 596 shares in the last quarter. UMB Bank n.a. raised its holdings in shares of Ultragenyx Pharmaceutical by 118.8% during the fourth quarter. UMB Bank n.a. now owns 606 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 329 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in shares of Ultragenyx Pharmaceutical by 97.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 1,831 shares of the biopharmaceutical company’s stock worth $65,000 after acquiring an additional 903 shares in the last quarter. International Assets Investment Management LLC raised its holdings in shares of Ultragenyx Pharmaceutical by 3,182.4% during the fourth quarter. International Assets Investment Management LLC now owns 1,674 shares of the biopharmaceutical company’s stock worth $80,000 after acquiring an additional 1,623 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC raised its holdings in shares of Ultragenyx Pharmaceutical by 38.3% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,979 shares of the biopharmaceutical company’s stock worth $95,000 after acquiring an additional 548 shares in the last quarter. Hedge funds and other institutional investors own 97.67% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. Wedbush reissued a “neutral” rating and set a $48.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, April 16th. JPMorgan Chase & Co. increased their target price on shares of Ultragenyx Pharmaceutical from $88.00 to $92.00 and gave the stock an “overweight” rating in a research report on Monday, March 18th. Canaccord Genuity Group increased their target price on shares of Ultragenyx Pharmaceutical from $110.00 to $111.00 and gave the stock a “buy” rating in a research report on Wednesday, February 21st. Cantor Fitzgerald reissued an “overweight” rating and set a $107.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Friday, April 5th. Finally, TD Cowen increased their target price on shares of Ultragenyx Pharmaceutical from $59.00 to $61.00 and gave the stock a “buy” rating in a research report on Wednesday. Two research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Ultragenyx Pharmaceutical presently has an average rating of “Moderate Buy” and an average target price of $88.08.

Ultragenyx Pharmaceutical Trading Down 1.0 %

RARE traded down $0.43 on Thursday, hitting $43.85. 470,806 shares of the stock traded hands, compared to its average volume of 758,706. Ultragenyx Pharmaceutical Inc. has a 52 week low of $31.52 and a 52 week high of $54.98. The firm has a market capitalization of $3.61 billion, a PE ratio of -5.32 and a beta of 0.65. The business has a fifty day moving average price of $47.94 and a two-hundred day moving average price of $43.75.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.65) by $0.13. The firm had revenue of $127.39 million for the quarter, compared to analyst estimates of $119.38 million. Ultragenyx Pharmaceutical had a negative return on equity of 369.54% and a negative net margin of 139.70%. The company’s quarterly revenue was up 23.3% compared to the same quarter last year. During the same period in the previous year, the company posted ($2.16) earnings per share. On average, equities research analysts forecast that Ultragenyx Pharmaceutical Inc. will post -6.36 EPS for the current fiscal year.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, Director Matthew K. Fust sold 12,195 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $50.88, for a total transaction of $620,481.60. Following the sale, the director now directly owns 14,860 shares of the company’s stock, valued at $756,076.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Ultragenyx Pharmaceutical news, Director Matthew K. Fust sold 12,195 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $50.88, for a total transaction of $620,481.60. Following the sale, the director now directly owns 14,860 shares of the company’s stock, valued at $756,076.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider John Richard Pinion sold 4,173 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $53.76, for a total value of $224,340.48. Following the sale, the insider now directly owns 89,268 shares in the company, valued at $4,799,047.68. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 32,116 shares of company stock valued at $1,645,983. 6.80% of the stock is currently owned by corporate insiders.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.